Advances in the pharmaceutical treatment options for canine osteoarthritis

Pye, C ORCID: 0000-0003-1761-8125, Bruniges, N, Peffers, M ORCID: 0000-0001-6979-0440 and Comerford, E ORCID: 0000-0002-5244-6042 (2022) Advances in the pharmaceutical treatment options for canine osteoarthritis JOURNAL OF SMALL ANIMAL PRACTICE, 63 (10). pp. 721-738. ISSN 0022-4510, 1748-5827

Text Advances_in_the_Pharmaceutical_Treatment_Options_for_Canine_Osteoarthritis.REVISED_MANUSCRIPT2.14.02.22 (1).docx - Author Accepted Manuscript Download (196kB)

Abstract

Canine osteoarthritis is a significant cause of pain in many dogs and can therefore compromise animal welfare. As the understanding of the biology and pain mechanisms underpinning osteoarthritis grows, so do the number of treatments available to manage it. Over the last decade, there have been a number of advances in the pharmaceutical treatment options available for dogs with osteoarthritis, as well as an increasing number of clinical trials investigating the efficacy of pre-existing treatments. This review aims to examine the current evidence behind pharmaceutical treatment options for canine osteoarthritis, including non-steroidal anti-inflammatory drugs, piprants, monoclonal antibodies, adjunctive analgesics, structure modifying osteoarthritis drugs and regenerative therapies.

Item Type:	Article
Uncontrolled Keywords:	Animals, Dogs, Osteoarthritis, Pain, Dog Diseases, Analgesics, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Pharmaceutical Preparations
Divisions:	Faculty of Health & Life Sciences
Depositing User:	Symplectic Admin
Date Deposited:	09 Mar 2022 16:12
Last Modified:	16 Jun 2026 10:18
DOI:	10.1111/jsap.13495
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3150450
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.